Outlook Therapeutics, Inc. Common Stock (OTLK) is a publicly traded Healthcare sector company. As of May 21, 2026, OTLK trades at $0.27 with a market cap of $27.70M and a P/E ratio of -0.23. OTLK moved +18.21% today. Year to date, OTLK is -49.69%; over the trailing twelve months it is -83.94%. Its 52-week range spans $0.16 to $6.98. Analyst consensus is buy with an average price target of $3.25. Rallies surfaces OTLK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Outlook Therapeutics Narrows Q2 Loss to $4.5M, Swiss LYTENAVA Deal: Outlook Therapeutics reported a Q2 FY2026 net loss of $4.5 million versus $46.4 million a year ago, driven by cost restructuring and lower European unit sales. The company expanded LYTENAVA distribution through a Swiss agreement targeting 2027 launch and awaits an FDA decision on ONS-5010 this month.
| Metric | Value |
|---|---|
| Price | $0.27 |
| Market Cap | $27.70M |
| P/E Ratio | -0.23 |
| EPS | $-1.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.98 |
| 52-Week Low | $0.16 |
| Volume | 109.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.41M |
| Net Income | $-60.96M |
| Gross Margin | -85.05% |
2 analysts cover OTLK: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.25.